financetom
Business
financetom
/
Business
/
Travelers' Q3 Core Income, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Travelers' Q3 Core Income, Revenue Rise
Oct 16, 2025 5:00 AM

07:19 AM EDT, 10/16/2025 (MT Newswires) -- The Travelers Companies ( TRV ) reported Q3 core income Thursday of $8.14 per diluted share, up from $5.24 year earlier.

Analysts polled by FactSet expected $6.39.

Revenue for the quarter ended Sept. 30 was $12.47 billion, up from $11.90 billion a year earlier.

Analysts surveyed by FactSet expected $11.69 billion.

Travelers shares were down more than 4% in recent Thursday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal
Jul 24, 2024
07:40 AM EDT, 07/24/2024 (MT Newswires) -- Cannabis company Tilray Brands ( TLRY ) announced Wednesday that subsidiary Tilray Medical has received official approval for a new medical cannabis extract in Portugal. This follows the approval of Tilray Medical whole flower THC 18, and for the first cannabis extract in Portugal earlier this year. This is a significant step towards...
Top Premarket Gainers
Top Premarket Gainers
Jul 24, 2024
07:37 AM EDT, 07/24/2024 (MT Newswires) -- Dermata Therapeutics ( DRMA ) shares more than doubled, reversing Tuesday's slump. Pieris Pharmaceuticals ( PIRS ) shares surged 78% after the company agreed to merge with Palvella Therapeutics in an all-stock deal. Regencell Bioscience ( RGC ) shares advanced 40%, extending Tuesday's rally. Perfect Moment ( PMNT ) shares were up 7%,...
Pfizer Says Phase 3 Study of Potential Gene Therapy in Hemophilia Meets Goals
Pfizer Says Phase 3 Study of Potential Gene Therapy in Hemophilia Meets Goals
Jul 24, 2024
07:39 AM EDT, 07/24/2024 (MT Newswires) -- Pfizer ( PFE ) said Wednesday its phase 3 study evaluating its investigational gene therapy giroctocogene fitelparvovec in adults with moderately severe to severe hemophilia met its primary and secondary goals of superiority compared with prophylaxis. After a single dose, participants posted a statistically significant reduction in mean annualized bleeding rates compared to...
IDB and Brazil's public banks to launch Amazon ETF, say sources
IDB and Brazil's public banks to launch Amazon ETF, say sources
Jul 24, 2024
RIO DE JANEIRO, July 24 (Reuters) - The Inter-American Development Bank (IDB) and Brazil's public banks will announce on Thursday the development of an exchange-traded fund (ETF) focused on sustainable investments in the Amazon rainforest, said two people with direct knowledge. State development bank BNDES, Banco do Brasil and Caixa Economica Federal are part of the initiative, said the sources,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved